- Home
- ZTO vs CANF Comparison
ZTO vs CANF Comparison
Compare ZTO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTO
- CANF
- Stock Information
- Founded
- ZTO 2002
- CANF 1994
- Country
- ZTO China
- CANF Israel
- Employees
- ZTO N/A
- CANF N/A
- Industry
- ZTO Advertising
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ZTO Consumer Discretionary
- CANF Health Care
- Exchange
- ZTO Nasdaq
- CANF Nasdaq
- Market Cap
- ZTO N/A
- CANF 7.9M
- IPO Year
- ZTO 2016
- CANF N/A
- Fundamental
- Price
- ZTO $19.07
- CANF $1.13
- Analyst Decision
- ZTO Buy
- CANF Strong Buy
- Analyst Count
- ZTO 4
- CANF 2
- Target Price
- ZTO $25.13
- CANF $14.00
- AVG Volume (30 Days)
- ZTO 2.9M
- CANF 423.1K
- Earning Date
- ZTO 05-14-2025
- CANF 05-06-2025
- Dividend Yield
- ZTO 3.61%
- CANF N/A
- EPS Growth
- ZTO N/A
- CANF N/A
- EPS
- ZTO 1.12
- CANF N/A
- Revenue
- ZTO $6,066,599,984.00
- CANF $674,000.00
- Revenue This Year
- ZTO $9.23
- CANF $461.72
- Revenue Next Year
- ZTO $10.36
- CANF N/A
- P/E Ratio
- ZTO $17.03
- CANF N/A
- Revenue Growth
- ZTO 15.26
- CANF N/A
- 52 Week Low
- ZTO $16.34
- CANF $1.22
- 52 Week High
- ZTO $27.50
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ZTO 50.52
- CANF 35.40
- Support Level
- ZTO $18.48
- CANF $1.14
- Resistance Level
- ZTO $19.67
- CANF $1.27
- Average True Range (ATR)
- ZTO 0.81
- CANF 0.12
- MACD
- ZTO 0.12
- CANF -0.02
- Stochastic Oscillator
- ZTO 81.98
- CANF 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).